Key Highlights
- Moderna shares climbed approximately 13% to reach $67.50, marking the strongest closing price since September 2024, driven by investor day announcements.
- The biotech firm unveiled mRNA-6007, its inaugural in vivo CAR-T therapy, aimed at treating autoimmune conditions such as lupus, with clinical trials scheduled to commence in 2027.
- A unanimous 9-0 vote from an FDA advisory committee supported approval of Moderna’s flu vaccine for individuals aged 50 and above, with final regulatory action anticipated by August 5, 2026.
- Jefferies analyst Andrew Tsai increased his price objective to $53 from $45, while Piper Sandler’s Edward Tenthoff boosted his target to $77, reaffirming an Overweight stance.
- The Street’s consensus rating currently stands at Hold, with a mean price objective of $45.42 — suggesting potential downside from present trading levels.
Moderna (MRNA) shares skyrocketed approximately 13% during Friday’s trading session, climbing to $67.50 and positioning the biotech company for its strongest closing performance since September 2024. The impressive rally placed MRNA among the S&P 500’s leading gainers for the day. Intraday trading saw shares spike nearly 15%, approaching the $69 mark.
The driving force behind this surge was the company’s investor day presentation, during which management unveiled an ambitious expansion of its therapeutic pipeline that extends far beyond its COVID-19 vaccine foundation.
MRNA has now appreciated roughly 42% throughout the past month, signaling a notable transformation in market perception.
The standout disclosure involved Moderna’s inaugural in vivo CAR-T initiative, designated mRNA-6007. The organization intends to launch clinical trials in 2027, with initial focus on B-cell-driven autoimmune disorders, particularly systemic lupus erythematosus.
In vivo CAR-T technology reprograms a patient’s T-cells directly within the body, offering superior efficiency and reduced costs compared to conventional ex vivo approaches that necessitate cell extraction, laboratory modification, and subsequent reinfusion.
Moderna isn’t the sole player pursuing this innovative technology. Eli Lilly made a strategic acquisition of Orna Therapeutics earlier this year precisely to access its in vivo CAR-T capabilities. Lilly’s shares also advanced 6% on Friday, buoyed by favorable European regulatory decisions concerning its oral oncology therapy.
Strategic Pipeline Architecture Spanning Three Phases
Moderna presented its forward-looking roadmap organized into three separate “horizons.” The initial phase emphasizes established, near-commercial assets encompassing current marketed products and advanced-stage development programs.
Jefferies analyst Andrew Tsai projects the company could potentially commercialize upwards of seven therapeutic products spanning respiratory, oncology, and rare disease categories within the next two years. This would represent a substantial expansion beyond its current three-vaccine portfolio.
Tsai highlighted anticipated Phase III melanoma trial results during the latter half of 2026 as a critical upcoming milestone, characterizing it as “a major event” for shareholder value. His rating remains at Hold despite elevating his price objective to $53 from $45.
Another program attracting significant attention is mRNA-4194, Moderna’s pioneering cancer prevention therapy, designed for Lynch syndrome patients. The firm is simultaneously progressing mRNA-1195, its multiple sclerosis treatment candidate, which should yield preliminary data during 2026.
Influenza Vaccine Provides Additional Momentum
Beyond oncology and autoimmune applications, Moderna’s influenza vaccine contender mRNA-1010 received validation when an FDA advisory committee delivered a unanimous 9-0 endorsement for approval targeting adults 50 years and older.
The FDA will render its ultimate determination on August 5, 2026. Regulatory clearance would provide the company with an additional revenue-generating product beyond the COVID-19 franchise.
Piper Sandler analyst Edward Tenthoff elevated his price objective to $77 from $69 while maintaining an Overweight recommendation, citing the momentum demonstrated during the investor presentation.
Notwithstanding optimism from select analysts, the comprehensive Wall Street consensus maintains a Hold posture, reflecting two Buy ratings, 19 Hold recommendations, and three Sell opinions compiled over the preceding three months. The average price target registers at $45.42, implying more than 31% potential downside from current price levels.
